• NASDAQ article reports verticalization, specialization of data and analytics platforms will take on growing importance in coming year
• Sequire platform offers new level of domain expertise, knowledge
• Since its launch, Sequire has gained more than 1 million active investors, traders from 91 public companies

A recent NASDAQ article noting the top 10 data analytics trends for 2021 reported that the verticalization and specialization of data and analytics platforms will take on growing importance in the new year (https://ibn.fm/irU4C). SRAX (NASDAQ: SRAX), a digital marketing and consumer data-management technology company, appears to be ideally positioned to thrive within those expectations. “The need for analytics is well-established, and generic platforms that crunch data and create visualizations have matured,” reported the NASDAQ article, which was titled “What Data Analytics Will Look Like in 2021 — And How to Capitalize On It.” The article continued, noting that “enterprises will now expect a level of domain expertise and knowledge of how data and analytics can support specific use cases, and thus will gravitate towards platforms that can meet their needs more specifically with capabilities such as risk modeling for insurance, or in the case of Signals Analytics, marketing intelligence to support the product life cycles. With 80% of analytics projects failing, this will be one way that companies will be able to buck the trend.” Domain expertise and knowledge is at the core of Sequire, an investor intelligence and communications platform created by SRAX in 2019. Sequire gathers and analyzes data about stock buyers’ behaviors and trends for issuers of publicly traded companies, allowing those issuers to use audience insights to capture the interest of existing investors and attract new ones. Since its launch, Sequire has gained more than 1 million active investors and traders from 91 public companies (https://ibn.fm/eSG5s). Originally called SRAX IR, the data-management platform was renamed Sequire because that name better represents the platform’s main objective of gathering, managing and analyzing data to acquire and secure investors for publicly traded companies (https://ibn.fm/71Mus). Sequire’s intelligent technologies distinguish it from other offerings in the world of data collection and reinforce the company’s focus on innovation and uniqueness in the marketplace (https://ibn.fm/51XDL). SRAX is dedicated to building the largest and most reliable opted-in data sets across many industry verticals; accurately identifying target consumers for brands and companies in the CPG, investor relations, luxury, and lifestyle spaces; and keeping those brands ahead in the competitive curve with high-quality data. The Company also provides other verticals, including SRAX Core, a custom digital media-management platform that enables brands and agencies to surpass the challenges of omnichannel marketing campaigns; SRAX Social, a free social media management tool that makes it easy for brands, agencies and individuals to grow their digital presence; SRAX Auto, which unlocks auto intenders’ data to create measurable connected experiences on the road to purchase; SRAX Shopper, which delivers a cross-channel, premium digital experience at scale to high-value shopper audiences; and SRAX Lux, which targets and reaches consumers at luxury retail stores as well as high-end art, music, film, fashion and sports events, across all consumer devices. For more information about SRAX and Sequire, visit the companies’ websites at www.SRAX.com and www.MySequire.com. NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• The rapidly growing industry expected to be worth $100 billion by 2024.
• Players seek user-friendly experience that is easy, convenient.
• Creative approaches utilized to gain new players, retain gamers, and increase daily engagement and wagering volumes

The industry of iGaming, or the playing of or betting on the outcome of a game or event on the internet, is rapidly growing, and Mobius Interactive is strategically positioned to benefit from that growth. Mobius is an online gaming operator that caters to diverse demographic groups through creative brand offerings, onboarding, retention and engagement strategies. According to an article published by Techie Gamers, iGaming is one of the fastest-growing industries on the planet, estimated to be worth approximately $100 billion by 2024 (https://ibn.fm/8k929). iGaming encompasses sports betting, online casino betting, poker betting, online video gaming, virtual horseracing and more. Sports betting and casino games make up the majority of the industry. The reason for this growth, according to Techie Gamers, is the combination of fast-paced technological advancements and an increase in mergers and acquisitions. Trends for this industry show continued growth due to creative software providers and gaming operators. While players seek out a user-friendly experience that is easy and convenient, providers are looking for a way to attract new players while increasing gameplay and retention. As competition in the market increases, savvy companies such as Mobius that are committed to staying ahead of the game are creating customizations with themes, stories and more. Mobius currently has three diverse brand offerings that launched in September 2020. Each caters to a specific audience.

• Aragon Casino’s target market is 21- to 45-year-olds and uses medieval fantasy themes
• Club Double’s target market is 30- to 65-year-olds, and uses old Hollywood and vintage Miami and Las Vegas themes
• MobiusBet’s target market is the younger 18- to 38-year-old eSports community

The company is setting itself apart in the iGaming industry. Mobius’ creativity extends beyond its distinctive themes. The company has partnered with and is utilizing more than 600 VIP affiliates to bring in high-value players. In addition, Mobius is introducing a unique loyalty and gamification program to increase customer engagement once customers are brought onto the platform. Real-time CRM systems allow the company to personalize customer experience in an interactive and highly intelligent manner. These combined methods work to increase sign up, daily engagement and wagering volumes. The future of the iGaming industry looks promising with eSports and casino games leading the way. This is great news for Mobius — and not unexpected. After all, the company’s leadership team has brought with it massive amounts of hands-on experience and combined is responsible for the launch of 30 successful products in just the last three years. As people turn to the safety and comfort of online betting from their own couches, Mobius is strategically building a strong foundation of well-timed launches and collaborations to become a leader in the iGaming industry. For more information, visit the company’s website at www.MobiusInteractive.Ltd. NOTE TO INVESTORS: The latest news and updates relating to Mobius are available in the company’s newsroom at http://ibn.fm/Mobius

• Strong growth in US lumber demand has led to both record price increases – and record levels of timber, tree debris along with it
• Sustainable Green Team has sought to introduce environmentally sustainable solution to storm, tree debris removal sector
• Via purchase of Mulch Manufacturing in February 2020, SGTM is now able to process tree biomass it collects into premium mulch products
• SGTM has perfected its vertically integrated business model – retailing environmentally friendly agricultural product while simultaneously getting compensated for collecting necessary raw materials

Lumber demand in the United States has never been higher; according to the National Association of Home Builders (“NAHB”), lumber prices rose by 30 percent between the onset of Hurricane Harvey in August 2017 and January 2018 on the back of strong reconstruction-driven demand (https://ibn.fm/ncKQM). However, recent price trends have put even that rally to shame. Since mid-April 2020, lumber prices have risen by over 130% (https://ibn.fm/5Oh35), with the Covid-19 pandemic driving a virtual exodus of residents from large urban metropolis’ and spurring a wave of new housing starts elsewhere in the country. However, the phenomenon has also led to record levels of timber wastage – leading to a sharp increase in the demand for the Sustainable Green Team (OTC: SGTM), a vertically integrated storm and debris removal company’s services. Sustainable Green Team has historically sought to provide a synergistic and environmentally beneficial solution to tree and storm waste disposal, in a bid to alleviate the environmental burdens which have traditionally afflicted landfills and disposal sites around the country. Accordingly, throughout its 40-year corporate tenure, SGTM has worked to cultivate a reputation as an environmentally responsible enterprise, focused on being “stewards of the environment” across all aspects of their business. A perennial challenge for SGTM and its peer companies within the sector has been to find a sustainable solution for the treatment and handling of tree debris, which has habitually been sent to local landfills and disposal sites. The company sought to address this issue through the purchase of Ohio-based Mulch Manufacturing, a leader in the field of manufacturing mulch used for agricultural and landscaping purposes in February 2020 (https://ibn.fm/A70mT). Following its merger with Mulch Manufacturing, SGTM has been able to move beyond the traditional waste disposal model, rather opting to process the collected tree biomass into a variety of organic, attractive, and next-generation mulch products which are packaged and sold on to retailers, landscapers, installers and garden centers. Sold under the Softscape(R) brand name, Mulch Manufacturing’s mulch and landscaping products allow water and air to penetrate soil and roots, a vital function to promote plant health and growth (https://ibn.fm/F2qid). SGTM has been able to translate its acquisition into ongoing commercial success, recently revealing that its subsidiary, Mulch Manufacturing Inc., had been awarded contracts to supply The Kroger Co. and Alimentation Couch-Tard’s Circle K subsidiary with premium grade organic mulch products over the course of 2021 (https://ibn.fm/SeD5q). In addition to its efforts in recycling tree and storm waste into commercialized mulch products, the Sustainable Green Team has recently gained the International Play Equipment Manufacturers Association (“IPEMA”) certification to commence recycling waste into playground surfacing material. With demand for playground surfacing material rapidly rising as a result of growing demand from the likes of schools, commercial athletic facilities and recreational spaces, SGTM’s new product line is expected to help the company tap into a market which is estimated to rise to a value of over $5.8 billion by the end of 2026, a 150% increase from 2017’s $3.7 billion (https://ibn.fm/OlJEM). As environmental concerns continue to build across the world, the need to find sustainable solutions within the tree and debris management sector has gained increased prominence. Through its vertically integrated structure, SGTM has now managed to achieve the rarest goal of them all – building a sustainable and commercially viable business in an increasingly essential sector of the economy. To learn more about Sustainable Green Team, please visit www.NationalArborCare.com and view the investor presentation at https://ibn.fm/dL5kn NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://ibn.fm/SGTM

• Pure Extracts Technologies Corp. has announced plans to expand, build fourth unit in dedicated towards research, development of psilocybin
• Announcement on its expansion plans come shortly after the Company revealed it plans to apply to Health Canada for a Dealer’s License
• Award of Dealer’s License would allow Pure Extracts to cultivate, harvest and procure controlled substances and carry out research into psychedelic compounds such as psilocybin and psilocin – paving way towards future commercialization of its product
• The Dealer’s License application has taken on increased relevance following Health Canada’s decision to revise existing regulations to permit certain authorized uses of psilocybin-assisted psychotherapeutic treatments

Pure Extracts Technologies (CSE: PULL) (XFRA: A2QJAJ), a plant-based extraction company, recently revealed that it had begun the buildout of the fourth unit in its 10,000 square foot purpose built and British Columbia-based facility for the extraction of mushrooms in order to conduct research and development of psilocybin under a Dealer’s License (https://ibn.fm/3qqJe). The news of its expansion plans come shortly after Pure Extracts announced that the Company would be applying to Health Canada for a Dealer’s License under the Controlled Drugs and Substances Act (“CDSA”). The CDSA, which oversees the legal access to controlled substances and regulates the production, distribution, and sale of these substances in Canada, requires companies to obtain regulatory approval from Health Canada prior to carrying out activities within the sector (https://ibn.fm/fcgs3). Further to the announcement regarding the license application, Pure Extracts also seized the opportunity to state that the Company had retained a globally recognized operations, compliance, and regulatory firm to advise on its application to thereby ensure the Company’s adherence to the criteria put forth by the regulatory body. If obtained, the Dealer’s License would enable Pure Extracts to cultivate, harvest and procure controlled substances – including the likes of psychedelic mushrooms for the purpose of psilocybin extraction, conduct research into controlled substances and ultimately engage in the sale of these substances through a variety of different channels. “As a plant-based extractor bringing functional mushroom products to market in Q1 2021, we are very excited to be building-out our facility for our move into the controlled substances world of psychedelics,” commented Pure Extracts’ CEO Ben Nikolaevsky regarding the expansion plans. “It’s great to have space adjacent to our cutting-edge facility which is built to Health Canada standards and to know that this space will also have the same high standards of construction that Pure Extracts prides itself on.” The planned application has gained further relevance in light of Health Canada’s recent decision to revise the Special Access Programme (“SAP”) and related regulations to permit certain authorized uses of psilocybin-assisted psychotherapeutic treatments (https://ibn.fm/YA6ag). Initially announced on December 11, 2020, the revision of the SAP would effectively enable the use of mushroom extracts in a range of new medical applications—including within the complex and ever-broadening mental health sector. Pure Extracts seized the occasion to announce a collaboration with Dr. Alexander MacGregor, a distinguished Professor of Biopharmaceutics and current President of the Toronto Institute of Pharmaceutical Technology (“TIPT”) ahead of the proposed regulatory changes and the outcome of the Company’s Health Canada license application. Pure Extracts and Dr. MacGregor are set to collaborate on the development and research of optimum psilocybin extraction methodologies, thus laying the groundwork to service the needs of the rapidly advancing growth and demand within the sector. Nikolaevsky elaborated on Pure Extracts’ corporate prospects within the functional mushrooms space ahead of the anticipated regulatory changes, “The Special Access Programme may prove to be the tipping point and fundamental milestone event that eventually transforms an entire segment of the medical community’s outlook towards the treatment of mental health conditions. Here at Pure Extracts, we believe in the future of the mushroom-based drug development sector and are committed to building shareholder value based on the growing number of positive indicators for future success.” For more information, visit the company’s website at www.PureExtractsCorp.com. NOTE TO INVESTORS: The latest news and updates relating to PULL are available in the company’s newsroom at https://ibn.fm/PULL

• Market for CBD-based pain relief products is growing rapidly, projected to reach $20 billion by 2024
• CNSC is a biotech company that produces fast-acting CBD products under the Xceptol brand
• Xceptol products are formulated with exclusive technology that increases absorbability, bioavailability, shelf life
• Third-party testing on Xceptol suggests 400% increase in skin penetration, 300% increase in gut absorption when compared to regular oil-based CBD

CannAssist International (OTCQB: CNSC), owner of Xceptor Labs, is a biotechnological pharmaceutical and wellness company marketing the Xceptol consumer brand – a line of cannabidiol (“CBD”) products that promises increased absorption, bioavailability and longer shelf life. An aging population coupled with increased chronic stress among younger people contributes to the rapidly growing market for CBD-based pain relief products—a market projected to reach $20 billion by 2024 (https://ibn.fm/eJhu9). Cannabidiol – a therapeutic component of the cannabis plant—has been studied extensively and has been shown to reduce inflammation while providing pain relief (https://ibn.fm/SsOQw). As concerns about the dangerous toxicity of mainstream pharmaceuticals like Acetaminophen continue to rise (https://ibn.fm/eVMfu), more people than ever before are turning to CBD for a gentler way to relieve pain and reduce inflammation. CiBiDinol is created using a proprietary process specifically developed to overcome numerous critical issues with oil-soluble CBD molecules. These include treatment administration, absorbability, bioavailability, and the short shelf-life of oil-based CBD products. Through the company’s proprietary process, CBD molecules are combined with penetration-enhancing cyclodextrin to cover the surface of the oil-soluble CBD molecule in a water-soluble carrier rendering it water dispersible. The resulting product has been shown to enhance absorption through the skin and gut with the overall goal of administering CBD in a way that is better aligned with the body’s natural bioactivity. Due to increased absorption, CNSC believes that its technology also offers a more potent product with greater efficacy per dose. Testing conducted via third-party services has confirmed these claims, suggesting that products created with CiBiDinol demonstrate a 400% increase in skin penetration along with a 300% increase in the rate of gut absorption when compared to regular oil-based CBD (https://ibn.fm/9S1Ys). Given the outcome of these tests, the company believes that the amount of CBD needed to achieve the targeted therapeutic effects can be reduced significantly, resulting in reduced costs for both manufacturers and consumers. Since its launch in September 2020, the Xceptol line of products includes five National Drug Codes topical pain creams utilizing ingredients registered with the FDA, capsules and tinctures. Xceptol’s CiBiDinol products are sold online through the Range Me product marketplace along with geographical distributors across established sales channels in North America.  Efforts to establish international distribution channels are underway in Central America, South America, South Africa, the EU, the UK and the Philippines. With the goal of targeting the pain-relief market, Xceptol products will be marketed through multiple social media campaigns using celebrities and former athletes associated with Freedman Sports Promotional Relations. Headquartered in San Diego, California, CannAssist was established in May 2017 with the goal of providing superior CBD products for a growing diverse market. For more information, visit the company’s website at www.CannAssistInternational.com. NOTE TO INVESTORS: The latest news and updates relating to CNSC are available in the company’s newsroom at https://ibn.fm/CNSC

• 70% of those with epilepsy could live seizure-free lives if properly diagnosed, treated
• Machine-learning algorithms using EEG signals have potential to accurately predict epileptic seizures, allowing patient to take preventive measures
• NeuroCap provides cost-effective solution that is disrupting EEG market

Brain Scientific (OTCQB: BRSF) is modernizing brain diagnostics with cutting-edge technology that bridges the widening gap in access to quality care. The use of artificial intelligence (“AI”) and machine learning (“ML”) is at the forefront of improving epileptic patients’ access to neurological care.

According to the World Health Organization (“WHO”), 50 million people worldwide have epilepsy (https://ibn.fm/NUPCJ). Approximately 70% of those people could live seizure-free lives if properly diagnosed and treated. Seizures are controllable. Through a pilot program, WHO discovered that by merely training primary health-care providers to diagnose and treat epilepsy, more people would have access to the treatment they need.

However, with conventional methods the necessary diagnostic equipment is cumbersome, complicated, and expensive; it also requires a trained technician to administer the tests. A more portable, simple-to-administer test is needed to reach the majority worldwide.

In the United States alone, an estimated 2.3 million adults and more than 450,000 children and adolescents live with epilepsy, with an estimated 150,000 people diagnosed each year (https://ibn.fm/bbcbW). Tragically, access to neurological care is decreasing as the need grows. In 2017, 20 states were considered neurology deserts, meaning they had less than 10 neurologists per 10,000 patients (https://ibn.fm/gnbtU).

A 2019 Advisory Board brief, titled “Navigating the Neurologist Shortage,” reported that the situation was not improving (https://ibn.fm/rP1Nc). “Providers across the country currently struggle to hire neurologists—and the problem shows no sign of abating. Estimates show that demand for neurologists in 2025 will exceed supply by 19%,” the report observed. This makes the wait for essential diagnosis and treatment long — and sometimes dangerous.

The solution may well be BRSF’s neuro-tech ecosystem. This approach consists of the disposable NeuroCap(TM) and a portable wireless NeuroEEG(TM) amplifier. These products provide rural hospitals with easy access to EEG tests.

Machine learning has improved EEG analysis and solved several challenges. Brain Scientific is working on incorporating AI and machine learning processes into the analysis, which will be able to free neurologists from the manual, tedious, and time-consuming portions of their jobs, thereby allowing them to help more patients.

According “Machine Learning for Predicting Epileptic Seizures Using EEG Signals,” which was published in February 2020, when an epileptic seizure is predicted in advance it is possible to take preventative interventions (https://ibn.fm/GXlG2). Machine learning algorithms using EEG signals have the potential to accurately predict epileptic seizures. This state-of-the-art hope for epilepsy still has problems, “cost-effective and efficient hardware implementation remains the bottleneck.”

Brain Scientific is working to disrupt the expensive EEG market. The NeuroCap and NeuroEEG are both approved by the FDA and provide economic and disposable substitutes. Trained technicians are not required to administer the tests, and a neurologist does not have to be on-site to run the analysis. A telemedicine physician can read the results in real time, eliminating long waits, high costs and the risks of exposure to communicable diseases such as COVID.

Brain Scientific is working to make neurological care accessible for all who need it.

For more information, visit the company’s website at www.BrainScientific.com.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

• COVID-19 cases projected to continue to increase in coming weeks, months
• UMEBSNI is trusted supplier of FDA-approved COVID-19 rapid antigen test kits
• United Medical offers additional comprehensive programs for COVID-19 testing

Even as COVID-19 vaccines are finally being approved and distributed, the latest forecast from the Centers for Disease Control and Prevention (“CDC”) predicts that an up to 2 million new COVID-19 cases will likely be reported in the week ending Jan. 16, 2021 (https://ibn.fm/0cNyq). The global pandemic is not yet over, and United Medical Equipment Business Solutions Network Inc. (“UMEBSNI”) continues to move quickly to address the unique testing needs created by the ongoing virus.

As part of its efforts to provide essential services during the epidemic, UMEBSNI is a trusted supplier of FDA-approved COVID-19 rapid antigen test kits (https://ibn.fm/hZ43R). The COVID-19 IgG/IgM Rapid Test Cassette offered by United Medical detects coronavirus antibodies that appear in the bloodstream of individuals infected with the virus within 10 minutes. The test can also indicate whether a person has protection against the coronavirus.

Other features of the test include the following:

• FDA Emergency Use Authorization (“EUA”)
• Small sample sizes; works with whole blood, plasma and serum samples
• Shelf life of up to 24 months from date of manufacture
• Stored at room temperature or refrigerated (2 to 30°C)
• Available in quantities of 25

The kits are for medical professional use only and are approved for use in CLIA moderate- or high-complexity settings. In addition, verification of use case prior to shipping is mandatory.

The IgG/IgM rapid test kits are only the beginning of UMEBSNI’s commitment to offering comprehensive programs for COVID-19 testing. Other services provided by the company include pre-shift temperature checks, medical-grade face masks, hand-sanitizer stations, medical-grade nitrile gloves and face shields.

Finally, the company also offers a unique mobile solution. UMEBSNI mobile testing specialists and experienced medical staff members are available to provide onsite COVID-19 Rapid Testing and solutions to implement employee safety. Mobile units and medical staff are on call and are capable of nationwide deployment for extended periods of time.

United Medical Equipment Business Solutions Network is a provider of reliable resources and solutions to fit the ever-changing needs of an aging population that includes seniors and veterans, as well as those impacted by the COVID-19 pandemic. Uniquely poised to offer health care across the continuum of care, United Medical Equipment has solutions that help providers work more proficiently, health-care systems work smarter and patients live healthier lives.

The company aims to provide the information, technology and proper equipment needed to maintain safety and health among seniors, veterans, health-care workers and other patients.

For more information, visit the company’s website at www.UnitedMedSolutions.com.

NOTE TO INVESTORS: The latest news and updates relating to United Medical Equipment are available in the company’s newsroom at https://ibn.fm/UnitedMed

• U.S. taking actionable steps toward acceptance of psilocybin
• States, individual cities have decriminalized, made use and possession of psilocybin low law-enforcement priority
• More psilocybin research being done focused on health, well-being of Americans facing a mental health crisis on epic levels

Cybin (NEO: CYBN) is a life science company focused on the pharmaceutical development of psychedelic products. The company’s subsidiary Serenity Life Sciences is focused on the research and development of psilocybin-based medications. Psilocybin, referred to by the media as magic mushrooms, has had its share of bad press. The stigma of this substance has halted R&D in America in the past, but that is beginning to change. Under the Controlled Substances Act, psilocybin is included with heroin and LSD as a Schedule I drug. According to the National Drug Intelligence Center, psilocybin serves no legitimate medical purpose in the United States (https://ibn.fm/Z23k3). This view has come under criticism as recent studies surrounding the substance show otherwise. The public’s opinion, state guidelines and pharmaceutical development of psychedelic products are moving towards growing acceptance and legalization. Oregon became the first state to legalize the use of psilocybin for therapeutic use when voters passed Measure 109 on Nov. 3, 2020 (https://ibn.fm/TKCuc), the latest in several steps the country hs been taking toward psilocybin acceptance. In 2005 the Court of Appeals in New Mexico overturned a felony drug trafficking conviction by citing that growing hallucinogenic mushrooms isn’t prohibited under the drug trafficking law’s definition of “manufacture” (https://ibn.fm/yRUSw), marking one of the first indications of what would be a slow-changing tide. Fifteen years later, New Jersey amended a marijuana decriminalization bill to include a lesser punishment for possession of psilocybin from a third-degree felony to a disorderly persons offense (https://ibn.fm/dmb3p). In addition, where states are not decriminalizing psilocybin, individual cities are. Denver was the first U.S. city to decriminalize psilocybin mushrooms. Ordinance 301 was passed with a 50.56% majority in May 2019 (https://ibn.fm/pX7ii). This ordinance keeps the city from prosecuting or arresting adults in possession of or even growing the mushrooms. Other cities across the country have followed suit. Oakland, California, passed a law the following month banning law enforcement from investigating and prosecuting individuals using or possessing drugs sourced from plants, cacti and mushrooms that contain psilocybin (https://ibn.fm/nEBhR). The third city was also in California. Santa Cruz’s City Council voted unanimously in January 2020 to make the investigation and arrest for adult possession, use or cultivation a low-priority infraction (https://ibn.fm/YlVE9). In another unanimous vote in September 2020, Ann Arbor, Michigan’s City Council voted in favor of declaring the investigating and arrest of anyone for planting, cultivating, purchasing, transporting, distributing, engaging in practices with or possessing psilocybin the city’s lowest law enforcement priority (https://ibn.fm/pooRa). All four cities citied indigenous cultural reasons as well as research around the use of psychedelics in the treatment of mental health and as a viable option combating the opioid crisis. More movement is being seen in the decriminalization and push for research across the United States.

• Alexandria Ocasio-Cortez filed legislation for researchers to more easily study the benefits of psychedelic drugs (https://ibn.fm/vDEHF)
• Jeff Shipply filled a bill in the name of personal freedom to decriminalize psilocybin in Iowa
• Initiative 81, voted on by D.C. residents and awaiting review by Congress, makes the possession and use of certain psychedelic plants low priority for the police (https://ibn.fm/yT730)

Criminalization and the stigmas attached have made it difficult for researchers to explore the medical benefits of psilocybin and other psychedelics. As more states accept the cultural and medical benefits of these substances, more research can be done, which could ultimately lead to increased health and well-being of Americans who are facing a mental health crisis on epic levels. With more than 17 million people in the Unted States experiencing at least one major depressive episode (https://ibn.fm/0Wxky), it is past time for new treatment alternatives. Cybin is at the forefront of companies conducting clinical trials for potential new treatment options and is developing innovative approaches to bring new psychedelic-based therapies to patients in need. For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• UUUU to receive minimum of 2,500 tons of natural monazite ore, one of highest-grade REE minerals in world
• Company to produce raw materials needed for clean energy, advanced technologies while also creating green jobs in economically underserved area
• Energy Fuels will be first U.S. company in years to produce marketable mixed REE concentrate on commercial scale

Energy Fuels (NYSE American: UUUU) (TSX: EFR), a diversified uranium miner, has finalized a three-year agreement with the Chemours Company (NYSE: CC) to obtain natural monazite ore, one of the highest-grade rare earth element (“REE”) minerals in the world (https://ibn.fm/Rp4YN). The agreement calls for Energy Fuels to receive a minimum of 2,500 tons per year and represents a significant step in UUUU’s commitment to be a leader in re-establishing a fully integrated U.S. REE supply chain.

“With our announcement . . .  Southeast Utah is fast becoming America’s clean energy and critical minerals hub,” Energy Fuels president and CEO Mark S. Chalmers stated. “Our goal is to domestically produce the raw materials needed for clean energy and advanced technologies, while creating green jobs in an economically challenged part of the country.

“Currently, the U.S. imports nearly all of our rare earth, uranium and vanadium requirements, despite having ample supplies here in the U.S.,” Chalmers continued. “Importantly, in the United States we are highly regulated and operate to the highest standards, which means we produce these minerals more responsibly than many of the countries from which we currently import. Our agreement with Chemours may be the beginning of a real success story, not only for Energy Fuels, but also for local communities, Native Americans, conservation groups, the State of Utah, and the U.S. as a whole.”

Based on the announcement, Energy Fuels intends to start process the monazite it receives from Chemours beginning the first quarter of 2021. The process will take place at UUUU’s wholly owned White Mesa Mill, which is located in Utah. The company will recover the uranium that results from that process and produce a marketable mixed REE carbonate, an essential step toward re-establishing a fully independent U.S. REE supply chain.

Once Energy Fuels successfully begins this process, UUUU will be the first company in the United States in years to produce a marketable mixed REE concentrate ready for separation on a commercial scale. Based on its estimates, UUUU plans to be able to provide almost 10% of total current U.S. REE demand. REEs are used in a wide variety of clean energy and advanced technologies, including wind turbines, electric vehicles, cell phones, computers, flat-panel displays, advanced optics, catalysts, medicine and national defense applications.

Energy Fuels’ mixed REE carbonate production from monazite ore should use only a  small amount of its White Mesa Mill’s ore-production capacity and produce almost no waste. Initially, UUUU plans on obtaining the 2,500 tons of monazite sands from Chemours, as outlined in the contract, but the company will work to increase monazite ore supply, hopefully reaching approximately 15,000 tons of monazite ore per year. The White Mesa Mill is licensed and designed to process 2,000 tons of ore daily, or 720,000 tons of ore per year, so the anticipated production of monazite sands represents an estimated 2% of its throughput capacity. If successful at reaching those numbers, Energy Fuels projects its White Mesa Mill will be able to produce approximately 50% of U.S. REE demand in a mixed REE carbonate.

For more information, visit the company’s website at www.EnergyFuels.com.

NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU

• Demand for food increasing as world population swells; pesticides paramount to maintain supply
• Countries banning pesticides deemed hazardous, but alternatives are lacking
• MustGrow is solution provider for global food supply with its natural biological crop protection for high-value crops

As the world population is increasing at an accelerated pace, a stable food supply is becoming critical to ensure food availability across the world. MustGrow (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) is playing a key role in providing biotechnology that secures both steady and high-quality crop supply.

To ensure a consistent flow of produce, crops need protection. For that, producers have been using various synthetic pesticides, which have become irreplaceable in creating a stable and abundant food supply for the global population. Indispensable for controlling weeds, pests and plant pathogens that threaten crops, synthetic pesticides contribute to higher yields and improved quality.

Still, not all of pesticides are created equal; some have even been deemed hazardous by the World Health Organization (“WHO”). Some pesticides on that hazardous list are still being used around the world, including in the United States. A recent article cites that around 150 agricultural pesticides considered hazardous to human health by WHO were used in the United States within the last few years (https://ibn.fm/wVmJt).

Although using potentially risky compounds has been an accepted part of the global food industry, the pressure to move away from that is growing. Both industry and governments are increasingly recognizing the importance of natural products to secure a quality food supply for the world while keeping health and safety in mind.

Although some jurisdictions are more advanced in scrutinizing the use of chemical pesticides in human consumption at present — resulting in some of those substances being banned — with globally integrated food supply chains, the world will likely see the convergence of these regulations on the international scale. As this happens, natural alternatives to chemical pesticides will become paramount to ensure a steady stream of crops while also adhering to strict health and safety standards (https://ibn.fm/3kU0S).

As bans on certain chemical pesticides continue to spread, natural alternatives are needed to fill this gap and secure the global food supply. To transition effectively away from chemical pesticides, new “biological” products need to have not only a safer and more eco-conscious profile but comparable efficacy and pricing as well. This is where MustGrow steps in.

As an agriculture biotech company committed to creating natural biological crop protection for high-value crops, MustGrow positions itself as a critical part of the food ecosystem of the future. The company has developed EPA-approved biotechnology that uses the mustard seed’s natural defense mechanism to protect plants from pests and diseases, offering a natural solution as an increasing number of markets seek natural alternatives for chemical pesticides.

Focused on developing breakthroughs in agriculture to enable farmers to use natural, safe and efficient products, MustGrow is a part of the solution to the global food supply problem with its unique, natural and organic product. As the market gap widens, MustGrow’s solution is showing comparable efficacy, consistency and potentially price compared to traditional synthetic chemicals, opening a global opportunity for the pioneering company to leverage the rising demand and help maintain both stable and high-quality food supply.

For more information, visit the company’s website at www.MustGrow.ca.

NOTE TO INVESTORS: The latest news and updates relating to MGROF are available in the company’s newsroom at https://ibn.fm/MGROF